within Pharmacolibrary.Drugs.ATC.L;

model L02BX04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 0.00049,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.39,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 10.020000000000001,            
    Vdp             = 2.93,
    k12             = 70.5,
    k21             = 70.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02BX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Relugolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced prostate cancer and uterine fibroids. It works by reducing the amounts of luteinizing hormone and follicle-stimulating hormone, thereby lowering testosterone or estrogen levels. It is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult males with advanced prostate cancer after multiple oral doses. Parameters are based on data from healthy adult volunteers and prostate cancer patients.</p><h4>References</h4><ol><li><p>George, DJ, et al., &amp; Shore, ND (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. <i>Clinical genitourinary cancer</i> 21(3) 383–392.e2. DOI:<a href=&quot;https://doi.org/10.1016/j.clgc.2023.03.009&quot;>10.1016/j.clgc.2023.03.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37062659/&quot;>https://pubmed.ncbi.nlm.nih.gov/37062659</a></p></li><li><p>Barretta, M, et al., &amp; Grandi, G (2024). The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> None 1–13. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2441981&quot;>10.1080/17425255.2024.2441981</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39666595/&quot;>https://pubmed.ncbi.nlm.nih.gov/39666595</a></p></li><li><p>Hafron, J, et al., &amp; Pruett, J (2023). Adherence to Hormonal Therapies in Prostate Cancer. <i>Urology practice</i> 10(6) 540–546. DOI:<a href=&quot;https://doi.org/10.1097/UPJ.0000000000000445&quot;>10.1097/UPJ.0000000000000445</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37647139/&quot;>https://pubmed.ncbi.nlm.nih.gov/37647139</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02BX04;
